Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 29
Filter
1.
Open Forum Infect Dis ; 9(2): ofab626, 2022 Feb.
Article in English | MEDLINE | ID: mdl-35071683

ABSTRACT

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection elicits varying degrees of protective immunity conferred by neutralizing antibodies (nAbs). In this study, we report the persistence of nAb responses over 12 months after infection despite their decreasing trend noticed from 6 months. METHODS: The study included sera from 497 individuals who had been infected with SARS-CoV-2 between January and August 2020. Samples were collected at 6 and 12 months after onset. The titers of immunoglobulin (Ig)G to the viral nucleocapsid protein (NP) and receptor-binding domain (RBD) of the spike protein were measured by chemiluminescence enzyme immunoassay. The nAb titer was determined using lentivirus-based pseudovirus or authentic virus. RESULTS: Antibody titers of NP-IgG, RBD-IgG, and nAbs were higher in severe and moderate cases than in mild cases at 12 months after onset. Although the nAb levels were likely to confer adequate protection against wild-type viral infection, the neutralization activity to recently circulating variants in some of the mild cases (~30%) was undermined, implying the susceptibility to reinfection with the variants of concerns (VOCs). CONCLUSIONS: Coronavirus disease 2019 convalescent individuals have robust humoral immunity even at 12 months after infection albeit that the medical history and background of patients could affect the function and dynamics of antibody response to the VOCs.

2.
Front Microbiol ; 12: 661187, 2021.
Article in English | MEDLINE | ID: mdl-34025615

ABSTRACT

Objective: There is scarce evidence regarding the long-term persistence of neutralizing antibodies among coronavirus disease 2019 (COVID-19) survivors. This study determined neutralizing antibody titers (NT50) and antibodies against spike protein (SP) or nucleocapsid protein (NP) antigens approximately 6 months after the diagnosis of COVID-19. Methods: COVID-19 survivors in Japan were recruited. Serum samples and data related to patients' characteristics and COVID-19 history were collected. NT50 and titers of antibodies against NP and SP antigens were measured at 20-32 weeks after the first positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test results. Factors associated with NT50 were identified using the multivariable linear regression and the correlations among NT50 and titers of immunoglobulin G (IgG) and total immunoglobulins (Igs) against NP and SP were assessed by Spearman's correlation. Results: Among 376 participants (median [range] days after testing positive for SARS-CoV-2, 180 (147-224); median [range] years of age, 50 (20-78); 188 [50%] male), most tested positive for NT50 (n = 367, 98%), SP-IgG (n = 344, 91%), SP-total Ig (n = 369, 98%), NP-IgG (n = 314, 84%), and NP-total Ig (n = 365, 97%). Regression analysis indicated that higher BMI, fever, and the requirement of mechanical ventilation or extracorporeal membrane oxygenation were significantly associated with higher NT50. Anti-SP antibodies correlated moderately with NT50 (Spearman's correlation: 0.63 for SP IgG; 0.57 for SP-total Ig), while the correlation was weak for anti-NP antibodies (0.37 for NP IgG; 0.32 for NP-total Ig). Conclusions: Most COVID-19 survivors had sustained neutralizing antibodies and tested positive for SP-total Ig and NP-total Ig approximately 6 months after infection.

3.
Neurol Med Chir (Tokyo) ; 48(11): 481-7; discussion 487-8, 2008.
Article in English | MEDLINE | ID: mdl-19029774

ABSTRACT

Growth hormone-releasing hormone (GHRH) stimulates not only the synthesis and secretion of GH but also the proliferation of normal somatotrophs. The expression of GHRH receptor (GHRHR) is regulated by GHRH, both of which are known to be expressed in human GH-secreting pituitary adenoma cells. Somatic mutations in the subunit of Gsalpha protein (gsp), lead to the constitutive activation of adenylyl cyclase in pituitary adenomas that secrete GH. It has not been examined how gsp mutations influence GHRHR expression in GH-secreting adenomas. We therefore analyzed the expression levels of GHRHR messenger ribonucleic acid (mRNA) in GH-secreting pituitary adenomas focusing on a gsp mutation. Furthermore, we investigated the effect of GHRH on the expression of GHRHR mRNA in primary cultures of GH-secreting pituitary adenoma cells. GHRHR mRNA expression levels were significantly elevated in gsp mutation-positive GH-secreting adenomas compared with those in gsp mutation-negative ones. In primary-cultured GH-secreting adenoma cells, the increase of GH secretion in response to GHRH was shown in both gsp mutation-positive and -negative adenoma cells with a significantly higher response in the latter adenoma cells. GHRH increased GHRHR mRNA expression level in gsp mutation-negative adenoma cells while it was not influenced by GHRH in gsp mutation-positive adenoma cells. These results suggest that gsp mutations up-regulate GHRHR mRNA expression in GH-secreting pituitary adenoma cells, and that gsp mutations desensitize the adenoma cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.


Subject(s)
Adenoma/genetics , GTP-Binding Protein alpha Subunits, Gs/genetics , Growth Hormone-Releasing Hormone/metabolism , Mutation, Missense , Neoplasm Proteins/genetics , Nerve Tissue Proteins/genetics , Pituitary Neoplasms/genetics , Point Mutation , RNA, Messenger/biosynthesis , RNA, Neoplasm/biosynthesis , Receptors, Neuropeptide/genetics , Receptors, Pituitary Hormone-Regulating Hormone/genetics , Acromegaly/etiology , Acromegaly/surgery , Adenoma/metabolism , Adenoma/pathology , Adult , Amino Acid Substitution , Cell Line, Tumor/drug effects , Cell Line, Tumor/metabolism , Female , GTP-Binding Protein alpha Subunits, Gs/physiology , Gene Expression Regulation, Neoplastic , Growth Hormone-Releasing Hormone/pharmacology , Humans , Male , Middle Aged , Neoplasm Proteins/biosynthesis , Nerve Tissue Proteins/biosynthesis , Pituitary Neoplasms/metabolism , Pituitary Neoplasms/pathology , Receptors, Neuropeptide/biosynthesis , Receptors, Pituitary Hormone-Regulating Hormone/biosynthesis
4.
Endocr Pathol ; 19(1): 17-26, 2008.
Article in English | MEDLINE | ID: mdl-18228160

ABSTRACT

The functional differentiation of pituitary cells and adenomas follows the combination of transcription factors and co-factors in three cell lineages [growth hormone-prolactin-thyroid-stimulating hormone lineage, adrenocorticotrophic hormone (ACTH)/pro-opiomelanocortin (POMC) lineage, and follicular stimulating hormone (FSH)/luteinizing hormone (LH) lineage], which include Pit-1, GATA-2, SF-1, NeuroD1/beta2, Tpit, ERalpha, and others. Only rarely are hormones from different lineages co-expressed in the same adenoma cells. Most corticotroph cell adenomas belonging to the ACTH/POMC lineage are mono-hormonal. In our study of 89 corticotroph cell adenomas, 5 cases expressed both ACTH and alpha-subunit; these adenomas did not express any other anterior pituitary hormones or subunits. To clarify the mechanism involved, we studied the transcription factors that regulate pituitary cell differentiation. NeuroD1 and T-pit, markers of the ACTH/POMC lineage, and SF-1 and DAX-1, related to the LH/FSH cell lineage were expressed in all cases. GATA2, a synergistic factor in the gonadotroph cell lineage with SF-1, was also expressed in three of five cases. As ACTH and alpha-subunit are the earliest hormones to appear during development, we speculate that these particular adenomas are derived from committed ACTH progenitor cells. The molecular process governing functional differentiation of these adenomas requires further investigation.


Subject(s)
Adenoma/genetics , Adrenocorticotropic Hormone/genetics , Gene Expression Regulation, Neoplastic , Glycoprotein Hormones, alpha Subunit/genetics , Pituitary Neoplasms/genetics , Pituitary Neoplasms/pathology , Adenoma/blood , Adenoma/pathology , Adolescent , Adrenocorticotropic Hormone/blood , Adult , Aged , Basic Helix-Loop-Helix Transcription Factors/genetics , Female , Helix-Loop-Helix Motifs/genetics , Humans , Hydrocortisone/blood , Hydrocortisone/urine , Immunohistochemistry , Male , Middle Aged , Pituitary Neoplasms/blood , Pro-Opiomelanocortin/genetics , Transcription Factor Pit-1/genetics , Transcription Factors/genetics , Young Adult
5.
Endocr Pathol ; 18(4): 208-16, 2007.
Article in English | MEDLINE | ID: mdl-17987403

ABSTRACT

OBJECTIVE: The aim of this study was to determine the correlation between the expression of somatostatin receptors by immunohistochemistry and the percent suppression of GH levels in the octreotide suppression test. PATIENTS AND METHODS: Twenty-two patients with acromegaly who underwent an octreotide suppression test before surgery were studied. We performed immunohistochemistry for Somatostatin receptor 2A (SSTR2A) and Somatostatin receptor 5 (SSTR5) on the surgical specimens from all patients, which we scored according to the number of tumor cells staining positive at the surface membrane (3+: >50%, 2+: 25-50%, 1+: <25%). We sought correlations of percent suppression in the octreotide suppression test with these immunohistochemistry scores. RESULTS: Somatostatin receptor 2A (SSTR2A) showed the highest frequency of score 3+ (13 of 22, 59.1%) by immunohistochemistry. Subtype 5 showed the highest frequency for score 2+ (9 of 22, 40.9%), and one (4.5%) was immunonegative. For subtype 2A, there was a significant correlation with percent decrease (P = 0.002 < 0.01). In contrast, there was no significant correlation for SSTR5. CONCLUSION: Immunohistochemistry for SSTR2A in pathology specimens from acromegalic patients enabled selection of those experiencing clinical benefit from octreotide. Therefore, performing immunohistochemistry for detection of SSTR2A is recommended for all specimens obtained by surgery.


Subject(s)
Adenoma/metabolism , Antineoplastic Agents, Hormonal/therapeutic use , Growth Hormone-Secreting Pituitary Adenoma/metabolism , Octreotide/therapeutic use , Receptors, Somatostatin/biosynthesis , Acromegaly/drug therapy , Acromegaly/etiology , Adenoma/drug therapy , Adult , Aged , Female , Growth Hormone-Secreting Pituitary Adenoma/drug therapy , Humans , Immunohistochemistry , Male , Middle Aged , Neoadjuvant Therapy
6.
Endocr Pathol ; 18(1): 8-15, 2007.
Article in English | MEDLINE | ID: mdl-17652795

ABSTRACT

The pituitary tumor-transforming gene (PTTG) is a homolog of yeast Securin, which arrests the activation of Separin to induce sister chromatid separation in the transition from metaphase to anaphase. Pituitary tumor-transforming gene is also known to induce angiogenesis during pituitary tumorigenesis. It has not been clarified whether PTTG functions as a cytoplasmic or a nuclear protein. Our immunohistochemical study indicated that PTTG is localized in the cytoplasm of pituitary tumor cells. In the present study, confocal laser scanning microscopy (CLSM) analysis of human pituitary adenomas and immunoelectron microscopy of the mouse pituitary cell line, AtT-20, demonstrated the localization of PTTG in the Golgi apparatus and vesicles. Secreted PTTG was detected by immunoblotting from culture medium of mouse pituitary tumor cell lines. Our results suggested that PTTG is a secretory protein produced by pituitary tumor cells. In addition, PTTG may exert autocrine and/or paracrine functions as a newly proposed important pathway for the action of PTTG.


Subject(s)
Adenoma/metabolism , Cell Line, Tumor/metabolism , Neoplasm Proteins/metabolism , Pituitary Neoplasms/metabolism , Adenoma/pathology , Animals , Biomarkers, Tumor/metabolism , Blotting, Western , Cell Line, Tumor/pathology , Gene Expression , Humans , Image Processing, Computer-Assisted , Immunoenzyme Techniques , Mice , Microscopy, Confocal , Microscopy, Immunoelectron , Neoplasm Proteins/genetics , Pituitary Neoplasms/pathology , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Securin
7.
Endocr Pathol ; 17(2): 143-53, 2006.
Article in English | MEDLINE | ID: mdl-17159247

ABSTRACT

Human pituitary tumor transforming gene (hPTTG1) was recently identified as a protooncogene, which is a regulator of the cell cycle, as a homolog of yeast securin and a transcriptional activator of several angiogenic factors. Here we examined the relationships of hPTTG1 expression with cell proliferation, expression of the angiogenic factor, VEGF (vascular endothelial growth factor), and numbers of the blood vessels in the normal and/or adenomatous pituitary. With the exception of TSHoma, the expression of hPTTG1 was significantly higher in pituitary adenomas than in the normal pituitary gland. The cell proliferation activity was higher in pituitary adenomas than in the normal pituitary. Pituitary cell proliferation was significantly correlated with the level of hPTTG1 expression in the normal pituitary tissue, but there was no such correlation in the adenomas. The significant correlation of hPTTG1 with the VEGF expression and the numbers of the blood vessels was elucidated in pituitary adenomas. It is particularly noteworthy that immunohistochemical double staining indicated co-localization of VEGF in many hPTTG1-positive tumor cells. In conclusion, higher levels of hPTTG1 expression contribute to the pathobiology of pituitary adenomas by promoting angiogenesis rather than by activating cell proliferation, whereas hPTTG1 expression is related to mitotic activity in the normal pituitary gland.


Subject(s)
Adenoma/metabolism , Neoplasm Proteins/biosynthesis , Neovascularization, Pathologic/metabolism , Pituitary Neoplasms/metabolism , Adenoma/blood supply , Adenoma/pathology , Apoptosis/physiology , Cell Proliferation , Humans , Immunohistochemistry , Pituitary Neoplasms/blood supply , Pituitary Neoplasms/pathology , RNA, Messenger/analysis , Reverse Transcriptase Polymerase Chain Reaction , Securin , Vascular Endothelial Growth Factor A/metabolism
8.
Endocr Pathol ; 17(1): 35-43, 2006.
Article in English | MEDLINE | ID: mdl-16760578

ABSTRACT

The differentiation of pituitary cells and human pituitary adenomas follow three cell lineages: GH-PRL-TSH, ACTH, and FSH/LH, which are regulated by a combination of various transcription factors and co-factors. We have used RT-PCR and immunohistochemistry to show that immunonegative, "null cell" adenomas are equipped with multiple transcription factors and co-factors. The "null cell" adenomas showed similar frequencies of transcription factors as did the gonadotropin subunit (GnSU)-positive adenomas, with the exception that there were fewer instances of SF1 in the former. We speculate, therefore, that null cell adenomas and GnSU-positive adenomas share common molecular mechanisms in functional differentiation, even though the former do not produce hormones. From the high frequency of various transcription factors, we also speculate that both null cell adenomas and GnSU-positive adenomas are derived from "committed" pituitary progenitor stem cells. The questions, why a certain proportion of these pituitary tumor groups lack hormone production and why they are molecularly more committed to Gn transcription, remain to be further investigated.


Subject(s)
Adenoma/metabolism , Gonadotropins, Pituitary/metabolism , Pituitary Neoplasms/metabolism , Transcription Factors/biosynthesis , Adenoma/genetics , Adenoma/pathology , Adult , Aged , Cell Lineage , Cell Transformation, Neoplastic , DNA Primers/chemistry , Female , Gene Expression , Gonadotropins, Pituitary/genetics , Hormones/metabolism , Humans , Immunoenzyme Techniques , Male , Middle Aged , Pituitary Neoplasms/genetics , Pituitary Neoplasms/pathology , RNA, Messenger/metabolism , RNA, Neoplasm/analysis , Reverse Transcriptase Polymerase Chain Reaction , Transcription Factors/genetics
9.
J Vet Med Sci ; 68(1): 1-7, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16462109

ABSTRACT

Acute diabetes insipidus-like symptoms have been reported as a complication after hypophysectomy in dogs. These symptoms are believed to be the consequence of deficiency of arginine vasopressin (AVP) secretion. The symptoms spontaneously resolve within 2 weeks, but the mechanism is unclear. In the present study, AVP secretion related to increases in Na+ concentration and serum osmotic pressure was measured, and immunohistochemical analysis in the paraventricular and supraoptic nuclei was performed after hypophysectomy in normal dog. In the hypertonic saline test, the plasma AVP concentration slightly increased in hypophysectomized dogs, although the increase was markedly smaller than that in normal dogs. An immunohistochemical study of the hypothalamus nucleus revealed that, AVP-positive cells tended to decrease after hypophysectomy. It suggests that excision of the posterior lobe by surgery injured the axon of magnocellular neuron in the hypothalamus. A decrease in the function and the number of AVP-producing and -secreting magnocellular neurons after hypophysectomy, suggests that the clinical improvement of postoperative diabetes insipidus-like symptoms may not be related to the recovery of AVP secretion.


Subject(s)
Diabetes Insipidus/veterinary , Dog Diseases/etiology , Hypophysectomy/veterinary , Hypothalamo-Hypophyseal System/cytology , Hypothalamo-Hypophyseal System/physiopathology , Animals , Arginine Vasopressin/blood , Arginine Vasopressin/metabolism , Diabetes Insipidus/etiology , Dogs , Hypophysectomy/adverse effects , Immunohistochemistry , Osmotic Pressure , Sodium/blood
10.
Endocr Pathol ; 17(3): 263-75, 2006.
Article in English | MEDLINE | ID: mdl-17308363

ABSTRACT

This study aimed to immunohistochemically assess the proliferation activity of pituitary incidentalomas. A series of 52 incidentalomas studied included 22 gonadotroph cell adenomas, 21 null cell adenomas, and 9 clinically silent adenomas (identified as functioning by immunohistochemistry). We also analyzed the differences in proliferation activity between 43 non-functioning pituitary incidentalomas (not including 9 silent adenomas), and 43 symptomatic non-functioning adenomas (NFAs) that caused visual disturbance. Cell proliferation markers were immunostained using monoclonal Ki-67 (MIB-1) antibody and monoclonal anti-topoisomerase II alpha (Topo-II alpha) antibody. The average of MIB-1 labeling indices in pituitary incidentalomas was 0.61% +/- 0.06%. Overall, both MIB-1 and Topo-II alpha labeling indices of the incidentalomas were significantly lower than those of symptomatic NFAs. There were no significant differences in immunopositivity between the two groups based on gender, age, or subtype. The MIB-1 index of the smallest adenoma group in pituitary incidentalomas was significantly lower than in symptomatic NFAs, while the Topo-II alpha incidentaloma was significantly lower than in symptomatic NFAs. Our findings suggest that small or less invasive pituitary incidentalomas should be observed with follow-up MRI. Large or invasive incidentalomas should be surgically treated if the patients show visual disturbances, hypopituitarism, or pituitary apoplexy during the follow-up period.


Subject(s)
Adenoma/metabolism , Biomarkers, Tumor/analysis , Cell Proliferation , Incidental Findings , Pituitary Neoplasms/metabolism , Adenoma/pathology , Adult , Antigens, Neoplasm/metabolism , DNA Topoisomerases, Type II/metabolism , DNA-Binding Proteins/metabolism , Female , Humans , Ki-67 Antigen/metabolism , Magnetic Resonance Imaging , Male , Middle Aged , Pituitary Neoplasms/pathology
11.
Endocrine ; 28(1): 37-41, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16311408

ABSTRACT

The mechanisms of tumorigenesis of the human pituitary have been elucidated to a limited extent. Classically, pituitary tumor formation was shown to be induced by thyroidectomy and estrogen administration. Molecular biological and immunohistochemical studies have revealed several aspects of pituitary tumorigenesis. Translineage cell differentiation has been shown to be induced by the aberrant expression of transcription factors and co-factors, such as Pit-1, Prop-1, and estrogen receptor. Defects or overexpression of cell cycle regulators, such as CDK inhibitors, PTTG, and GADD45gamma, result in the abnormal proliferation of pituitary cells. Recently, epigenetic regulation has been suggested to be related to pituitary tumor formation. This article presents a review and update of recent progress in studies of the development and differentiation of pituitary tumors.


Subject(s)
Adenoma/etiology , Pituitary Neoplasms/etiology , Adenoma/chemically induced , Adenoma/genetics , Adenoma/pathology , Animals , Cell Cycle Proteins/metabolism , Gene Expression Regulation, Neoplastic , Humans , Mice , Pituitary Neoplasms/chemically induced , Pituitary Neoplasms/genetics , Pituitary Neoplasms/pathology , Transcription Factors/metabolism
13.
Semin Ultrasound CT MR ; 26(1): 47-50, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15771265

ABSTRACT

The development of computed tomography (CT) and magnetic resonance imaging (MRI) has resulted in the discovery of unsuspected endocrinologically silent pituitary masses (pituitary incidentalomas). The aim of this study was to clarify the natural history of pituitary incidentalomas in order to establish an appropriate approach to them. Five hundred fifty patients with pituitary incidentalomas were analyzed in this study; 261 patients (47.4%) underwent surgery (surgical group; SG), whereas 289 patients (52.6%) were followed up conservatively (nonsurgical group; NSG) for a mean period of 27.3 months (range, 6-173 months). Clinical and biochemical assessment, CT or MRI of the pituitary, and visual field testing were assessed at baseline and at 6 months and yearly thereafter. A total of 261 tumors in the SG group consisted of 211 (80.8%) nonfunctioning pituitary adenomas and 42 (16.1%) Rathke's cysts. During a follow-up period, of 289 tumors in the NSG group, 209 (72.3%) tumors stayed the same size as before, 35 tumors (12.1 %) increased in size, and 41 tumors (14.2%) decreased in size. The estimated diagnoses of the tumors that increased consist of 28 nonfunctioning pituitary adenomas, 5 Rathke's cyst, and 2 others. The decreased tumors consist of 11 nonfunctioning adenomas, 21 Rathke's cysts, and 3 others. Pituitary incidentalomas usually follow a benign course. We recommend transsphenoidal adenomectomy for a solid mass attached to the optic chiasma estimated to be a pituitary adenoma by MRI. Other patients should be followed up by MRI and biochemical assessment. Especially asymptomatic cystic masses (including Rathke's cleft cysts) could be followed up without surgical intervention because they tend to stay the same size or sometimes be cured spontaneously.


Subject(s)
Adenoma/therapy , Central Nervous System Cysts/therapy , Health Surveys , Incidental Findings , Pituitary Neoplasms/therapy , Adenoma/diagnosis , Adolescent , Adult , Aged , Aged, 80 and over , Central Nervous System Cysts/diagnosis , Disease Progression , Female , Follow-Up Studies , Humans , Japan , Magnetic Resonance Imaging/methods , Male , Middle Aged , Pituitary Gland/diagnostic imaging , Pituitary Gland/pathology , Pituitary Gland/surgery , Pituitary Neoplasms/diagnosis , Retrospective Studies , Tomography, X-Ray Computed/methods
14.
Front Horm Res ; 32: 20-33, 2004.
Article in English | MEDLINE | ID: mdl-15281338

ABSTRACT

This review article describes functional differentiation of the pituitary cells and pituitary adenomas with special emphasis on transcription factors and co-factors. Human pituitary adenomas generally follow the combination of transcription factors and co-factors, which are similar to those of physiologic anterior pituitary cells. On very rare occasions, the single pituitary adenoma produces two hormones, which belong to different cell lineage 'trans-cell lineage'. Basic mechanism for this was considered to be 'aberrant expression' of transcription factors, i.e. NeuroD1 and Pit-1. This was experimentally supported by the induction of GH (mRNA and protein) in AtT-20 cells by transfecting Pit-1 gene. Various mechanisms have been reported for the experimental pituitary oncogenesis. Among these, GHRH has been emphasized as one of oncogenic factors for both human GHomas as well as in the transgenic animals.


Subject(s)
Adenoma/metabolism , Adenoma/pathology , Pituitary Gland/metabolism , Pituitary Gland/pathology , Pituitary Neoplasms/metabolism , Pituitary Neoplasms/pathology , Animals , Cell Differentiation , Humans , Pituitary Gland/cytology , Pituitary Hormones/metabolism , Transcription Factors/metabolism
15.
Acta Neuropathol ; 108(2): 147-53, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15185102

ABSTRACT

Thyrotropin (TSH)-secreting adenomas are rare and, as most adenomas are large, invasive and difficult to cure by surgery only, many require additional medical treatment. Many TSH-secreting adenomas cosecrete growth hormone (GH) and/or prolactin (PRL). We evaluated the relationship between pathology and the effect of dopamine agonist bromocriptine and somatostatin analogue octreotide in 20 operated patients with TSH-secreting adenomas. The four men and 16 women ranged in age from 23 to 62 years; three had clinically overt acromegaly; two manifested galactorrhea-amenorrhea. Endocrinologically, elevated serum GH, and/or IGF-1 were observed in six patients and elevated serum PRL was observed in eight. Immunohistochemically, 16 of the 20 adenomas were positive for GH and/or PRL (GH-positive, n=13; PRL-positive, n=9). Pituitary-specific transcription factor Pit-1 was demonstrated in the nuclei of all adenoma cells. Octreotide tests showed suppression of serum TSH (<50%) in ten of 14 patients. Preoperative octreotide treatment effectively reduced serum TSH and tumor size in two patients. Electron micrographs of octreotide-treated TSH-secreting adenomas showed shrinkage of the cytoplasm and diffuse distribution of secretory granules. Our study suggests that cosecretion of GH and/or PRL from TSH-secreting adenoma has no correlation with response of tumor cells to medical treatment.


Subject(s)
Adenoma/pathology , Antineoplastic Agents, Hormonal/therapeutic use , Pituitary Neoplasms/pathology , Thyrotropin/metabolism , Adenoma/drug therapy , Adenoma/metabolism , Adenoma/ultrastructure , Adult , Bromocriptine/therapeutic use , Female , Growth Hormone/blood , Hormone Antagonists/therapeutic use , Humans , Immunohistochemistry/methods , Male , Microscopy, Electron/methods , Middle Aged , Octreotide/therapeutic use , Pituitary Neoplasms/drug therapy , Pituitary Neoplasms/metabolism , Pituitary Neoplasms/ultrastructure , Prolactin/blood , Retrospective Studies , Staining and Labeling
16.
Nihon Rinsho ; 62(5): 946-50, 2004 May.
Article in Japanese | MEDLINE | ID: mdl-15148824

ABSTRACT

The development of computed tomography(CT) and magnetic resonance imaging (MRI) has resulted in the discovery of unsuspected endocrinologically silent pituitary masses(pituitary incidentalomas). The management of these pituitary incidentalomas is controversial. Some lesions may increase in size, compress optic chiasm while others will remain unchanged in size. Five hundred and six patients with pituitary incidentalomas were obtained by questionnaire from March 1999 to May 2000 under the auspices of the Ministry of Health, Labor and Welfare in Japan. In thirty-three patients with pituitary incidentalomas (13.3%) developed tumor enlargement during the mean follow-up period of 45.5 months. Of 115 estimated non-functioning adenomas, 23(20.0%) tumor increased during mean follow up period of 50.7 months (range 10 to 173 months), while 5(5.4%) of 94 estimated Rathke's cysts increased in size during follow up. Pituitary apoplexy was occurred in one patient of 248 patients (0.4%). Pituitary incidentalomas usually follow a benign course. Transsphenoidal adenectomy is indicated for a solid mass attached to optic chiasma. For other patients, MRI every 6 months for the first 2 years, and then yearly may be recommended.


Subject(s)
Incidental Findings , Pituitary Neoplasms/epidemiology , Age Factors , Female , Follow-Up Studies , Humans , Japan/epidemiology , Magnetic Resonance Imaging , Male , Pituitary Neoplasms/diagnosis , Pituitary Neoplasms/surgery , Sex Factors , Surveys and Questionnaires , Time Factors , Tomography, X-Ray Computed
17.
Neurol Med Chir (Tokyo) ; 44(1): 29-32, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14959934

ABSTRACT

A 56-year-old woman presented with an intracranial osteosarcoma at the site of previous radiosurgery, manifesting as sudden onset of headache and left hemiparesis with aphasia. She had a previous history of stereotactic radiosurgery for an intracranial tumor under a diagnosis of falx meningioma. Computed tomography showed intratumoral and peritumoral hemorrhage at the right parietofrontal region. Gross total resection of the tumor with hematoma was performed. The histological diagnosis was osteosarcoma. Sarcomatous change is a rare complication of radiotherapy. This case illustrates that osteosarcoma may develop years after radiosurgery for benign brain neoplasm.


Subject(s)
Frontal Lobe/surgery , Meningeal Neoplasms/surgery , Meningioma/surgery , Neoplasms, Radiation-Induced/diagnosis , Neoplasms, Second Primary/diagnosis , Osteosarcoma/diagnosis , Parietal Lobe/surgery , Postoperative Complications/diagnosis , Radiosurgery/adverse effects , Female , Follow-Up Studies , Frontal Lobe/pathology , Humans , Magnetic Resonance Imaging , Meningeal Neoplasms/diagnosis , Meningioma/diagnosis , Middle Aged , Neoplasms, Radiation-Induced/pathology , Neoplasms, Radiation-Induced/surgery , Neoplasms, Second Primary/pathology , Neoplasms, Second Primary/surgery , Osteosarcoma/pathology , Osteosarcoma/surgery , Parietal Lobe/pathology , Postoperative Complications/pathology , Postoperative Complications/surgery , Reoperation , Tomography, X-Ray Computed
18.
Clin Endocrinol (Oxf) ; 59(5): 630-6, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14616888

ABSTRACT

OBJECTIVE: Ghrelin and its receptor, growth hormone secretagogue (GHS) receptor (GHSR), are expressed in the normal pituitary gland and various types of pituitary adenoma. Somatic mutations in the subunit of Gs alpha protein (gsp), which led to a constitutive activation of adenylyl cyclase, are reported in GH-producing pituitary adenomas. We analysed the relationship between ghrelin mRNA and GHSR mRNA expression levels in gsp mutation-positive and -negative GH-producing pituitary adenomas. PATIENTS: Pituitary adenoma tissue was obtained at surgery from 20 patients with acromegaly. METHODS: The expression levels of human ghrelin mRNA and GHSR mRNA were quantified using a competitive RT-PCR method. To detect the gsp mutations, amplified Gs alpha subunit cDNA fragments were sequenced directly using RT-PCR method. RESULTS: There was no significant difference in the expression of ghrelin mRNA between mutation-positive and -negative adenomas. The expression of GHSR mRNA was significantly lower in gsp mutation-positive than -negative adenomas. There was a significant negative correlation between the levels of ghrelin mRNA and GHSR mRNA expression in mutation-negative adenomas; no such correlation was found in mutation-positive adenomas. CONCLUSION: These results suggest that GHSR mRNA expression is downregulated by ghrelin in gsp mutation-negative GH-producing pituitary adenomas, and that changes in intracellular signalling pathways in gsp mutation-positive GH-producing pituitary adenomas affect the expression of G protein-coupled receptors such as GHSR. The absence of negative correlation between ghrelin and GHSR expression might be induced by lowered GHSR expression in gsp mutation-positive GH-producing adenomas.


Subject(s)
Adenoma/metabolism , Gonadotropin-Releasing Hormone/genetics , Human Growth Hormone/metabolism , Pituitary Neoplasms/metabolism , RNA, Messenger/analysis , Receptors, G-Protein-Coupled/genetics , Adult , Analysis of Variance , Female , GTP-Binding Protein alpha Subunits/genetics , Humans , Male , Middle Aged , Mutation , Receptors, Ghrelin , Reverse Transcriptase Polymerase Chain Reaction
19.
J Vet Med Sci ; 65(7): 801-4, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12939508

ABSTRACT

Four dogs diagnosed as pituitary-dependent hyperadrenocorticism were treated with transsphenoidal hypophysectomy and postoperative hormone supplementation therapy. On histological examination of the resected tissues, the tumors were ACTH-producing adenoma of the anterior lobe. Clinical signs such as alopecia and calcinosis cutis, as well as endocrinological abnormalities, were markedly alleviated after surgery. The clinical courses of these 4 dogs suggest that transsphenoidal hypophysectomy may be a useful treatment for pituitary-dependent hyperadrenocorticism.


Subject(s)
Adenoma/surgery , Adenoma/veterinary , Adrenocorticotropic Hormone/metabolism , Dog Diseases/surgery , Hypophysectomy/methods , Hypophysectomy/veterinary , Adenoma/metabolism , Adenoma/pathology , Animals , Dog Diseases/metabolism , Dog Diseases/pathology , Dogs , Female , Male , Pituitary Gland/surgery
20.
Eur J Endocrinol ; 149(2): 123-7, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12887289

ABSTRACT

OBJECTIVE: The development of computed tomography (CT) and magnetic resonance imaging (MRI) has resulted in the discovery of unsuspected endocrinologically silent pituitary masses (pituitary incidentalomas). The aim of this study was to perform a national survey on pituitary incidentalomas in order to establish an appropriate approach to them. DESIGN AND METHODS: Five hundred and six patients with pituitary incidentalomas were obtained by questionnaire from March 1999 to May 2000 under the auspices of the Ministry of Health, Labor and Welfare in Japan. Two hundred and fifty-eight patients underwent surgery (surgical group), while 248 patients were followed up conservatively for a mean period of 26.9 Months (range 6-173 Months) (non-surgical group). Clinical and biochemical assessment, CT or MRI of the pituitary, and visual field testing by Goldman perimetry were assessed at baseline and 6 Months and Yearly thereafter. RESULTS: Thirty-three patients with pituitary incidentalomas (13.3%) developed tumor enlargement during the mean follow-up period of 45.5 Months. Of 115 estimated non-functioning adenomas, 23 tumors (20.0%) increased during a mean follow-up period of 50.7 Months (range 10-173 Months), while 5 of 94 (5.3%) estimated Rathke's cysts increased in size during follow-up. Pituitary apoplexy occurred in one of 248 patients (0.4%). CONCLUSIONS: Pituitary incidentalomas usually follow a benign course. We recommend transsphenoidal adenectomy for a solid mass attached to the optic chiasma estimated to be a pituitary adenoma by MRI. Other patients should be followed up by MRI every 6 Months for the first 2 Years, and then Yearly.


Subject(s)
Pituitary Neoplasms/epidemiology , Adenoma/pathology , Adenoma/surgery , Adolescent , Adult , Aged , Aged, 80 and over , Child , Disease Progression , Female , Follow-Up Studies , Humans , Japan/epidemiology , Magnetic Resonance Imaging , Male , Middle Aged , Neurosurgical Procedures , Pituitary Apoplexy/etiology , Pituitary Neoplasms/surgery , Retrospective Studies , Tomography, X-Ray Computed , Visual Fields
SELECTION OF CITATIONS
SEARCH DETAIL
...